Medicare AdvantagePrior AuthHigh impact
MA08.121g, Pembrolizumab (Keytruda®)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Aug 24, 2026
We identified it
Aug 25, 2026
Summary
MA08.121g updates medical necessity criteria for Pembrolizumab (Keytruda®) effective immediately. This is a Medicare Advantage pharmacy policy change that may affect prior authorization requirements, coverage conditions, or documentation standards for this immunotherapy drug. The billing team must review the full policy text to identify specific changes to submission requirements.
Action Required
By 2026-08-24: Billing team must obtain and review the complete MA08.121g policy text from https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=08&FilterField2=MPSiteActivityLogYear&FilterValue2=2026. Identify specific changes to medical necessity criteria, prior authorization triggers, and documentation requirements for Pembrolizumab claims. Update billing system rules, prior auth workflows, and provider education materials accordingly. Oncology providers must be notified of any new documentation or authorization requirements. Failure to implement changes may result in claim denials for Pembrolizumab administrations under Medicare Advantage plans.